
RealRate

PHARMACEUTICAL 2019

Cellectar Biosciences Inc. Rank 290 of 371





PHARMACEUTICAL 2019

Cellectar Biosciences Inc. Rank 290 of 371

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 295% points.

The company's Economic Capital Ratio, given in the ranking table, is -465%, being 134% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	13,952
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,622
Liabilities, Non-Current	171
Other Assets	559
Other Compr. Net Income	0
Other Expenses	1,675
Other Liabilities	0
Other Net Income	92
Property and Equipment	543
Research and Development	6,835
Revenues	0
Selling, General and Administrative Expense	4,820

Output Variable	Value in 1000 USD
Assets	15,054
Liabilities	1,793
Expenses	13,331
Stockholders Equity	13,261
Net Income	-13,239
Comprehensive Net Income	-13,239
Economic Capital Ratio	-465%